News Room

Adcock Ingram acquires Brolene Eye Drops and STOP-ALLERG Eye Drops

In line with the company’s strategy to expand the product portfolios of the various divisions, Adcock Ingram Healthcare (Pty) Ltd. has acquired Brolene Eye Drops and STOP-ALLERG Eye Drops from Genop Healthcare (Pty) Ltd.  The responsibility for the marketing and distribution of these brands transferred to the OTC division of Adcock Ingram on 01 October 2016.

Brolene Eye Drops and STOP-ALLERG Eye Drops will augment the existing ophthalmology product offerings from Adcock Ingram, which are Allergex Eye Drops and Gemini Eye Drops, extending the company’s presence in this category. 

The OTC division of Adcock Ingram holds the leading positon in pharmacy in the OTC space.  Liquids make up a large and important section of the Adcock Ingram OTC product range.  Backed by the High Volume Liquids facility (HVL) situated in Clayville, the division is well positioned to manufacture and market a wide range of liquids, effervescents and powders.

‘We are delighted with these acquisitions which extend our offering in the ophthalmology space,’ said Werner van Rensburg, Managing Director of the Adcock Ingram OTC division.  ‘This is also in line with the company strategy to expand our portfolio and I believe that even though these products are mature, they have potential to grow with the support of the healthcare professionals and the enthusiasm of our sales force.’

Registration details: 

S0 Brolene Eye Drops contain propamidine isethionate 1 mg/ml.  Ref. No. H1212 (Act 101/1965).

S2 STOP-ALLERG Eye Drops contain sodium cromoglycate 20 mg/ml.  Reg. No. W/15.4/430

For full prescribing information, refer to the package insert approved by the medicines regulatory authority. 1009461 10/2016. Adcock Ingram Limited. Reg. No. 1949/034385/06. Private Bag X69, Bryanston, 2021, South Africa. Tel. +27 11 635 0000. www.adcock.com